Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 3

APPLIED GENETIC TECHNOLOGIES CORP

Form 3

March 26, 2014

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement APPLIED GENETIC TECHNOLOGIES CORP [AGTC] **INTERWEST PARTNERS** (Month/Day/Year) VIII LP 03/26/2014 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O INTERWEST (Check all applicable) PARTNERS. 2710 SAND HILL ROAD, SUITE 200 __X__ 10% Owner Director (Street) Officer Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) Form filed by One Reporting Person MENLO PARK, Â CAÂ 94025 _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative Security 2. Date Exercisable and 4. 5. **Expiration Date** Securities Underlying Ownership Beneficial (Instr. 4) Conversion (Month/Day/Year) or Exercise Form of Ownership **Derivative Security** (Instr. 4) Price of Derivative (Instr. 5) Derivative Security:

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A-1 Convertible Preferred Stock	(1)	(1)	Common Stock	690,699	\$ <u>(1)</u>	I	See footnote (2)
Series B-1 Convertible Preferred Stock	(3)	(3)	Common Stock	183,126	\$ (3)	I	See footnote (4)
Series B-2 Convertible Preferred Stock	(3)	(3)	Common Stock	339,825	\$ (3)	I	See footnote (5)
Series B-3 Convertible Preferred Stock	(3)	(3)	Common Stock	162,830	\$ (3)	I	See footnote (6)
Series B-1 Warrant (Right to Buy)	(3)(7)	05/02/2017	Series B Convertible Preferred Stock	416,361 (3)	\$ 0.1297	I	See footnote (8)

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
INTERWEST PARTNERS VIII LP C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
InterWest Management Partners VIII, LLC C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
INTERWEST INVESTORS VIII L P C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
INTERWEST INVESTORS Q VIII LP C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
GIANOS PHILIP T C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
Kliman Gilbert H C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 MENLO PARK, CA 94025	Â	ÂX	Â	Â		

Reporting Owners 2

Â

Holmes W Stephen

C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 Â Â X Â Â

MENLO PARK, CAÂ 94025

CASH HARVEY B

C/O INTERWEST PARTNERS 2710 SAND HILL ROAD, SUITE 200 Â Â X Â

MENLO PARK, CAÂ 94025

Signatures

/s/ W. Stephen Holmes, Managing Director 03/26/2014

**Signature of Reporting Person Date

/s/ W. Stephen Holmes, Managing Director 03/26/2014

**Signature of Reporting Person Date

/s/ W. Stephen Holmes, Managing Director 03/26/2014

**Signature of Reporting Person Date

/s/ W. Stephen Holmes, Managing Director 03/26/2014

**Signature of Reporting Person Date

/s/ Philip T. Gianos by Karen A. Wilson, Power of 03/26/2014

Attorney

**Signature of Reporting Person Date

/s/ Gilbert H. Kliman by Karen A. Wilson, Power of 03/26/2014

Attorney

**Signature of Reporting Person Date

/s/ W. Stephen Holmes 03/26/2014

**Signature of Reporting Person Date

/s/ Harvey B. Cash by Karen A. Wilson, Power of 03/26/2014

Attorney

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share of Series A-1 Convertible Preferred Stock is convertible into shares of Common Stock and will automatically convert (1) 1-for-16.62 basis upon closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

These securities are held as follows: 666,318 by InterWest Partners VIII, LP ("IW8"), 5,318 by InterWest Investors VIII, LP ("II8") and 19,063 by InterWest Investors Q VIII, LP ("IIQ8") (collectively, the "InterWest Funds"). InterWest Management Partners VIII, LLC

- (2) ("IMP8") is the General Partner of IW8, II8 and IIQ8 and has sole voting and investment control over the shares owned by IW8, II8 and IIQ8. Harvey B. Cash, Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP8 and disclaim beneficial ownership of those securities, except to the extent of their pecuniary interest therein.
- Each share of Series B-1, B-2 and B-3 Convertible Preferred Stock is convertible into Common Stock and will automatically convert

 (3) 1-for-35 basis upon closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

(4)

Signatures 3

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 3

These securities are held as follows: 176,662 by IW8, 1,410 by II8 and 5,054 by IIQ8. IMP8 is the General Partner of IW8, II8 and IIQ8 and has sole voting and investment control over the shares owned by IW8, II8 and IIQ8. Harvey B. Cash, Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP8 and disclaim beneficial ownership of those securities, except to the extent of their pecuniary interest therein.

- These securities are held as follows: 327,830 by IW8, 2,616 by II8 and 9,379 by IIQ8. IMP8 is the General Partner of IW8, II8 and IIQ8 and has sole voting and investment control over the shares owned by IW8, II8 and IIQ8. Harvey B. Cash, Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP8 and disclaim beneficial ownership of those securities, except to the extent of their pecuniary interest therein.
- These securities are held as follows: 157,083 by IW8, 1,253 by II8 and 4,494 by IIQ8. IMP8 is the General Partner of IW8, II8 and IIQ8 and has sole voting and investment control over the shares owned by IW8, II8 and IIQ8. Harvey B. Cash, Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP8 and disclaim beneficial ownership of those securities, except to the extent of their pecuniary interest therein.
- (7) The Series B-1 Warrant is exercisable for shares of Series B-1 convertible preferred stock at any time until the expiration of the warrant at the holder's election.
- These securities are held as follows: 401,663 by IW8, 3,206 by II8 and 11,492 by IIQ8. IMP8 is the General Partner of IW8, II8 and IIQ8 and has sole voting and investment control over the shares owned by IW8, II8 and IIQ8. Harvey B. Cash, Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP8 and disclaim beneficial ownership of those securities, except to the extent of their pecuniary interest therein.

Â

Remarks:

Exhibit List

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.